Effects of Biperiden and Amantadine on Memory in Medicated Chronic Schizophrenic Patients

1995 ◽  
Vol 166 (2) ◽  
pp. 241-243 ◽  
Author(s):  
H. Silver ◽  
N. Geraisy
Keyword(s):  
Retention Test ◽  
Digit Span ◽  
Double Blind ◽  
Logical Memory ◽  
Chronic Schizophrenic ◽  
Wechsler Memory Scale ◽  
Benton Visual Retention Test ◽  
Schizophrenic Patients ◽  
With Memory

BackgroundThe effects on memory of an anticholinergic (biperiden) and a dopaminergic (amantadine) anti-Parkinsonian agent were compared.MethodTwenty-six chronically medicated schizophrenic (DSM–III–R) in-patients received amantadine (200 mg/day) or biperiden (4 mg/day) for two weeks in a double-blind cross-over design.ResultsBiperiden treatment was associated with significantly lower scores on Benton Visual Retention Test (P< 0.003) and the visual subscale of Wechsler Memory Scale (WMS) (P≤ 0.02), with a trend to poorer scores on WMS total (P= 0.086) and the digit span (P= 0.07) and logical memory (P= 0.06) subscales.ConclusionsIn usual clinical doses, biperiden interferes with memory, particularly visual, more than amantadine.

The Withdrawal of Benztropine Mesylate in Chronic Schizophrenic Patients

1983 ◽  
Vol 143 (6) ◽  
pp. 584-590 ◽  
Author(s):  
Linda A. Baker ◽  
L. Y. Cheng ◽  
I. B. Amara
Keyword(s):  
Placebo Group ◽  
Test Scores ◽  
Drug Group ◽  
Extrapyramidal Symptoms ◽  
Antiparkinsonian Drug ◽  
Double Blind ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Wechsler Memory Scale ◽  
Schizophrenic Patients

SummaryIn this double-blind, four-week study, 28 chronic schizophrenic patients receiving neuroleptic medication plus the antiparkinsonian drug, benztropine mesylate, were either switched to placebo or maintained on benztropine. Patients withdrawn from benztropine reliably increased their overall scores on the Wechsler Memory Scale in comparison with the drug group. Sub-test scores suggest that deficits in attention and concentration were induced by treatment with benztropine. Psychotio decompensation appeared to develop simultaneously with extrapyramidal symptoms (EPS) in some patients, but only 14.2 per cent of the placebo group experienced extrapyramidal symptoms severe enough to require resumption of benztropine therapy. It is suggested that antiparkinsonian agents should be prescribed only if and when EPS occur.

A double-blind study with ceruletide in chronic schizophrenic patients: Biochemical and clinical results

1986 ◽  
Vol 19 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Margot Albus ◽  
Klaus von Gellhorn ◽  
Ursula Münch ◽  
Dieter Naber ◽  
Manfred Ackenheil
Keyword(s):  
Clinical Results ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

A Double-Blind Comparative Trial of Loxapine and Trifluoperazine in Acute and Chronic Schizophrenic Patients

1976 ◽  
Vol 4 (6) ◽  
pp. 441-448 ◽  
Author(s):  
L G Kiloh ◽  
S E Williams ◽  
D A Grant ◽  
P S Whetton
Keyword(s):  
Side Effects ◽  
Laboratory Tests ◽  
Urine Analysis ◽  
Comparative Trial ◽  
Chronic Patients ◽  
Double Blind ◽  
Anticholinergic Effects ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

A double-blind comparative trial of loxapine and trifluoperazine was carried out in 57 acute and chronic schizophrenic patients. In both groups of patients loxapine proved to be equivalent in its effects to trifluoperazine and there were suggestions it might be rather more effective in chronic patients. Side-effects were simitar with the two drugs but anticholinergic effects, excitement, dizziness and faintness occurred rather more commonly with loxapine. Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations showed no significant abnormalities.

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest
Keyword(s):  
Beneficial Effect ◽  
Recent Work ◽  
Controlled Trial ◽  
Pharmacokinetic Interaction ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

Activity in chronic schizophrenic patients: comparison of pimozide with fluphenazine in a double blind trial

1975 ◽  
Vol 5 (2) ◽  
pp. 161-164 ◽  
Author(s):  
A. C. P. Sims ◽  
I. G. Burnside
Keyword(s):  
Operant Conditioning ◽  
Crossover Trial ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Chronic Schizophrenic ◽  
Free Operant ◽  
Significant Difference ◽  
Schizophrenic Patients ◽  
Psychiatric Rating

SynopsisA double-blind crossover trial was carried out comparing pimozide with fluphenazine. The effects of the drugs on the activity of 20 chronic inert male schizophrenic patients were measured using nursing observations, psychiatric rating, and an operant conditioning method. When activity was assessed in these different ways, no significant difference was found between the two drugs on any of the measures. It is concluded that pimozide does not effectively increase the activity in such patients. It is considered that the free operant conditioning method used was shown to be a useful measure for comparing therapy in chronic schizophrenic patients.

Sign in / Sign up

Export Citation Format

Share Document